RXSF Why Buy? AMAZING DD  PRESCRIPTION DRUG ABUSE - A

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
RXSF Why Buy? AMAZING DD 

PRESCRIPTION DRUG ABUSE - A GLOBAL EPIDEMIC - Rx DrugSAFE - A REAL SOLUTION! 

Share Structure as of SEPT. 29,15 
A/S 500,000,000 ---- O/S 258,000,000 
*******Float 12,000,000******* 

INSIDERS BUYING UP EVERY LAST SHARE SINCE THURSDAY ALMOST 100,000,000, ONE FORM 4 WORTH $85,000 >>http://www.otcmarkets.com/stock/RXSF/filings 

New Top Rate Website 
http://www.rxdrugsafe.com/ 

DRUG SECURITY AND ADHERENCE Technology and Products that Make a Difference 

****There is no other company, nor any other team, that has as much experience and know-how in biometric technology as the Rx Safes**** 

*****Rx Safes, Inc. holds the exclusive worldwide rights to intellectual property that provides market protection for the fingerprint technology used in the Rx Safes’ products.***** 

PATENTED/TRADEMARKS/FDA REGISTERED 

Now you thought that was a good reason...Here's where it gets good. 

3 NYSE PARTNERS & HUGE Connections>> 

McKesson Corp.$179 Billion Annual Sales @ $192.00 PPS on NYSE 

Cardinal Health @ $91 Billion Annual Sales @ $79.50 PPS on NYSE 

Our current corporate partners include the biggest and most trusted names in the medical device and supply markets such as McKesson and Cardinal Health. We hold several patents and licenses to exclusively develop and offer our products for sale in North America. 

Next Huge Distribution PARTNER AMERISOURCE BERGEN $80 Billion Annual Revs & $100 pps on NYSE 

We have yet to establish a distribution agreement with Amerisource Bergen and anticipate that this will take approximately 3 months to develop the necessary relationships and establish an agreement. 

ALSO HONEYWELL, SENTRY LOCKS, MASTER LOCKS & OVERHEAD COMPANY 


https://en.m.wikipedia.org/wiki/AmerisourceBergen 

https://en.m.wikipedia.org/wiki/Cardinal_Health ; 

https://en.m.wikipedia.org/wiki/McKesson_Corporation 

AMAZING CONSUMER & COMMERCIAL PRODUCTS 

http://www.rxdrugsafe.com/our-products/consumer-products/ 
http://www.rxdrugsafe.com/our-products/profes...roducts/ 

Why we are different 
Our products and technology are more accurate, secure and convenient than traditional mechanical locks and pin codes. 
Our fingerprint technology provides superior controlled access to ONLY authorized persons. 
We offer the only biometric interface in portable, battery operated devices to target the healthcare market. 
Rx Safes’ technology and products simplify security. 
We can work with you to improve your existing products giving them a competitive advantage. 
We are pursuing a multi-pronged approached to drug security and safety. 

TOP RATE MANAGEMENT & BOARD 

http://www.rxdrugsafe.com/our-management-team/ 
http://www.rxdrugsafe.com/board-of-directors/ 

CEO Ms. Yarde was personally responsible for over $14 million in sales in the first production year, establishing extensive retail distribution relationships, major OEM partnerships and negotiated deals to acquire two key patents to support the growth of the business. As an entrepreneur, Ms. Yarde founded, owned and operated several private and public companies including a technology consulting organization called TekSource as well as a successful private commercial flooring organization, Gem Flooring, which at its peak employed over 20 installers and generated over $20 million in annual revenues. 

Co-Founder Mark Basile led one of those companies to a $460 million dollar public market cap. During his tenure as CEO at bioMETRX, the company pioneered a line of fingerprint home security products, culminating in over $14 million in sales in its first production year. Mr. Basile was also an original founding member of the E-Health Alliance – the worlds largest trade organization located in Washington D.C., focusing on electronic healthcare initiatives with all of the largest healthcare companies and organizations. Mr. Basile was directly instrumental in raising more than $45 million dollars for his prior companies, coordinated corporate takeovers of some of his companies largest competitors. 

Mr. Koch, age 49 currently holds the position of Executive Vice President and Chief Sales and Marketing Officer at Tweddle Group, Inc. ANNUAL REVENUES $127,000,000 

Here are all the News and Interviews/Videoshttp://www.rxdrugsafe.com/news/ 

The most effective solution 
See how TV, magazines and industry experts all agree that the protection provided by the Rx DrugSAFE is the most effective way to safeguard your prescription and OTC medications. 
FDA Registered 
Fingerprint recognition 
Quality all steel construction 
Simple and easy to use
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

CAPREIT Welcomes Francine Moore to Board of Trustees

Updated Category News Views 162

CAPREIT Welcomes Francine Moore to Board of Trustees CAPREIT is excited to share that Ms. Francine Moore has been appointed as a new member of its Board of Trustees. This appointment took effect on November 7. Francine is known for her significant experience in the real estate sector, where she has built a remarkable career. Ms. Moore's Impressive Background With over 25...

Continue Reading
Cimpress Sees Target Adjustments Yet Remains Strong – A Deeper Look

Updated Category News Views 95

Cimpress Stock Target Adjustments and Outlook Recently, Truist Securities made notable adjustments to the stock price target for Cimpress N.V. (NASDAQ: CMPR), a recognized leader in mass customization solutions. The new target is now set at $110.00, reduced from the previous $120.00. Despite this adjustment, the firm has reiterated a Buy rating, showcasing confidence in...

Continue Reading
Significant Shift in NICUs: Embracing Prolacta's Innovations

Updated Category News Views 131

Transforming Neonatal Care with Prolacta's Nutritional Innovations Prolacta Offers the Only Nutritional Products Free From Cow Milk and Added Synthetic Ingredients for Extremely Premature Infants in the U.S. In an exciting development for neonatal care, Prolacta Bioscience® has reported that in 2025, the majority of Level III and IV neonatal intensive care units (NICUs)...

Continue Reading
Orchestry Unveils Automated Workspace Solutions for Microsoft 365

Updated Category News Views 127

Orchestry Launches Innovative Workspace Review for Teams and SharePoint Orchestry has introduced a groundbreaking feature that aims to transform the way IT administrators manage collaboration workspaces within Microsoft 365. This new capability, known as Workspace Review, not only automates the maintenance of these workspaces but also enhances security and compliance...

Continue Reading
The Investment Journey of Webster Financial Over Five Years

Updated Category News Views 151

Understanding Webster Financial's Growth Over the Years Webster Financial (NYSE: WBS) has demonstrated remarkable performance in the stock market, consistently outperforming many competitors. Over the past five years, it has achieved an impressive average annual return of 15.04%, surpassing the market by 1.25% annually. This impressive growth reflects the ongoing...

Continue Reading